AR073396A1 - Derivados de 3-amino-indazol o de 3-amino-4, 5, 6, 7-tetrahidro-indazol - Google Patents

Derivados de 3-amino-indazol o de 3-amino-4, 5, 6, 7-tetrahidro-indazol

Info

Publication number
AR073396A1
AR073396A1 ARP090103663A ARP090103663A AR073396A1 AR 073396 A1 AR073396 A1 AR 073396A1 AR P090103663 A ARP090103663 A AR P090103663A AR P090103663 A ARP090103663 A AR P090103663A AR 073396 A1 AR073396 A1 AR 073396A1
Authority
AR
Argentina
Prior art keywords
group
substituted
cycloalkyl
alkoxy
hydroxy
Prior art date
Application number
ARP090103663A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR073396A1 publication Critical patent/AR073396A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Estos compuestos son moduladores del FXR y pueden utilizarse como medicamentos utiles para disminuir la absorcion de colesterol, se disminuye el colesterol LDL y los triglicéridos y se reduce la ateroesclerosis inflamatoria. Reivindicacion 1: Compuestos de la formula (1) en la que R1 es un anillo elegido entre el grupo formado por fenilo, naftilo y heteroarilo, dicho anillo está sin sustituir o sustituido por 1-3 sustituyentes elegidos con independencia entre el grupo formado por alquilo inferior, halogeno, halogenoalquilo inferior, hidroxi, alcoxi inferior, halogenoalcoxi inferior y ciano; R2, R3, R4 y R5 se eligen con independencia entre si entre el grupo formado por hidrogeno, halogeno y alquilo inferior; R2' y R3' juntos así como R4' y R5' juntos se reemplazan por un doble enlace, o R2', R3', R4' y R5' son hidrogeno; R6 se elige entre el grupo formado por alquilo inferior, cicloalquilo, alcoxialquilo inferior, fenilo sin sustituir o fenilo sustituido por 1-3 sustituyentes elegidos con independencia entre el grupo formado por alquilo inferior, halogeno, halogenoalquilo inferior, hidroxi, alcoxi inferior, halogenoalcoxi inferior, carboxilo, (alcoxi inferior)-carbonilo, alcoxicarbonilalquilo inferior, carboxilalcoxi inferior, alcoxicarbonilalcoxi inferior y ciano, fenilalquilo inferior, cuyo fenilo está sin sustituir o sustituido por 1-3 sustituyentes elegidos con independencia entre el grupo formado por alquilo inferior, halogeno, halogenoalquilo inferior, hidroxi, alcoxi inferior, halogenoalcoxi inferior y ciano, heterociclilo y heteroarilo sin sustituir o heteroarilo sustituido por 1-3 sustituyentes elegidos con independencia entre el grupo formado por alquilo inferior, halogeno, halogenoalquilo inferior, hidroxi, alcoxi inferior, halogenoalcoxi inferior y ciano; R7 se elige entre el grupo formado por hidrogeno, -C(O)-NH-R8, -C(O)-R9, -S(O)2-R10 y -C(O)-OR11; R8 se elige entre el grupo formado por alquilo inferior, cicloalquilo, cicloalquilo inferior, cicloalquilo sustituido por hidroxi, carboxilo, tetrazolilo o carboxilalquilo inferior, heterociclilo, fenilo sin sustituir y fenilo sustituido por 1-3 sustituyentes elegidos con independencia entre el grupo formado por alquilo inferior, halogeno, halogenoalquilo inferior, hidroxi, alcoxi inferior, halogenoalcoxi inferior, carboxilo, tetrazolilo, (alcoxi inferior)-carbonilo, alcoxicarbonilalquilo inferior, carboxilalquilo inferior, carboxilalcoxi inferior, alcoxicarbonilalcoxi inferior, ciano y cicloalquiloxi, cuyo resto cicloalquilo está sustituido por carboxilo; R9 se elige entre el grupo formado por alquilo inferior, cicloalquilo, cicloalquilo inferior y fenilalquilo inferior, cuyo fenilo está sin sustituir o sustituido por 1-3 sustituyentes elegidos con independencia entre el grupo formado por alquilo inferior, halogeno, halogenoalquilo inferior, hidroxi, alcoxi inferior, halogenoalcoxi inferior, carboxilo, tetrazolilo, (alcoxi inferior)-carbonilo, alcoxicarbonilalquilo inferior, carboxilalquilo inferior, carboxilalcoxi inferior, alcoxicarbonilalcoxi inferior, ciano y cicloalquiloxi, cuyo resto cicloalquilo está sustituido por carboxilo; R10 se elige entre el grupo formado por alquilo inferior, cicloalquilo, cicloalquilo inferior y fenilalquilo inferior, cuyo fenilo está sin sustituir o sustituido por 1-3 sustituyentes elegidos con independencia entre el grupo formado por alquilo inferior, halogeno, halogenoalquilo inferior, hidroxi, alcoxi inferior, halogenoalcoxi inferior, carboxilo, tetrazolilo, (alcoxi inferior)-carbonilo, alcoxicarbonilalquilo inferior, carboxilalquilo inferior, carboxilalcoxi inferior, alcoxicarbonilalcoxi inferior, ciano y cicloalquiloxi cuyo resto cicloalquilo está sustituido por carboxilo; y R11 se elige entre el grupo formado por alquilo inferior, cicloalquilo, cicloalquilo inferior, cicloalquilo sustituido por hidroxi, carboxilo, tetrazolilo o carboxilalquilo inferior, heterociclilo, fenilo sin sustituir y fenilo sustituido por 1-3 sustituyentes elegidos con independencia entre el grupo formado por alquilo inferior, halogeno, halogenoalquilo inferior, hidroxi, alcoxi inferior, halogenoalcoxi inferior, carboxilo, tetrazolilo, (alcoxi inferior)-carbonilo, alcoxicarbonilalquilo inferior, carboxilalquilo inferior, carboxilalcoxi inferior, alcoxicarbonilalcoxi inferior, ciano y cicloalquiloxi, cuyo resto cicloalquilo está sustituido por carboxilo; o las sales farmacéuticamente aceptables de los mismos.
ARP090103663A 2008-09-25 2009-09-23 Derivados de 3-amino-indazol o de 3-amino-4, 5, 6, 7-tetrahidro-indazol AR073396A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08165137 2008-09-25

Publications (1)

Publication Number Publication Date
AR073396A1 true AR073396A1 (es) 2010-11-03

Family

ID=41382044

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090103663A AR073396A1 (es) 2008-09-25 2009-09-23 Derivados de 3-amino-indazol o de 3-amino-4, 5, 6, 7-tetrahidro-indazol

Country Status (14)

Country Link
US (1) US8153663B2 (es)
EP (1) EP2346834B1 (es)
JP (1) JP5450632B2 (es)
KR (1) KR101444988B1 (es)
CN (1) CN102164900B (es)
AR (1) AR073396A1 (es)
AU (1) AU2009295967A1 (es)
BR (1) BRPI0919248A2 (es)
CA (1) CA2736434A1 (es)
ES (1) ES2443947T3 (es)
IL (1) IL211674A0 (es)
MX (1) MX2011002793A (es)
TW (1) TW201020234A (es)
WO (1) WO2010034657A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010034649A1 (en) * 2008-09-25 2010-04-01 F. Hoffmann-La Roche Ag 2,3-substituted indazole or 4,5,6,7-tetrahydro-indazoles as fxr modulators against dyslipidemia and related diseases
US8252826B2 (en) * 2010-03-24 2012-08-28 Hoffmann-La Roche Inc. Cyclopentyl- and cycloheptylpyrazoles
EP2593078B1 (en) * 2010-05-25 2016-11-30 Symrise AG Cyclohexyl carbamate compounds as active anti-cellulite ingredients
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
WO2013037482A1 (en) 2011-09-15 2013-03-21 Phenex Pharmaceuticals Ag Farnesoid x receptor agonists for cancer treatment and prevention
RS61540B1 (sr) 2013-09-11 2021-04-29 Inst Nat Sante Rech Med Postupci i farmaceutske kompozicije za tretiranje infekcije hepatitis b virusa
CA2968836A1 (en) 2016-06-13 2017-12-13 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
EP3730487B1 (en) 2016-06-13 2022-04-27 Gilead Sciences, Inc. Azetidine derivatives as fxr (nr1h4) modulators
SG11201906987RA (en) 2017-02-21 2019-09-27 Genfit Combination of a ppar agonist with a fxr agonist
PT3600309T (pt) 2017-03-28 2022-10-03 Gilead Sciences Inc Combinações terapêuticas para o tratamento de doenças hepáticas
CN110944635A (zh) 2017-03-30 2020-03-31 国家医疗保健研究所 用于减少附加体病毒的持久性和表达的方法和药物组合物
SI3911647T1 (sl) 2019-01-15 2024-04-30 Gilead Sciences, Inc. Izoksazolna spojina kot agonist FXR in farmacevtski sestavki, ki jo obsegajo
JP2022519906A (ja) 2019-02-19 2022-03-25 ギリアード サイエンシーズ， インコーポレイテッド Ｆｘｒアゴニストの固体形態
KR20220035365A (ko) 2019-07-18 2022-03-22 엔요 파마 인터페론의 부작용을 감소시키는 방법
WO2021144330A1 (en) 2020-01-15 2021-07-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of fxr agonists for treating an infection by hepatitis d virus
JP2024502673A (ja) 2021-01-14 2024-01-22 ウエヌイグレックオ・ファーマ Ｈｂｖ感染の処置のためのｆｘｒアゴニストとｉｆｎの相乗効果
JP2024517181A (ja) 2021-04-28 2024-04-19 ウエヌイグレックオ・ファーマ 組合せ治療としてｆｘｒアゴニストを使用するｔｌｒ３アゴニストの効果の強い増強
CN113372276B (zh) * 2021-05-25 2022-04-22 三峡大学 吲唑类衍生物及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1974379A (en) * 1932-10-12 1934-09-18 Cinch Mfg Corp Coupling device for hose and like connections
US1966325A (en) * 1933-06-28 1934-07-10 Verne E Welch Pump
GB865341A (en) * 1958-07-30 1961-04-12 Bayer Ag 5-benzene-sulphonamido-1-phenyl pyrazole derivatives
GB926327A (en) 1960-05-13 1963-05-15 Ici Ltd New dyestuffs of the azostilbene series containing halopyrimidyl residues
NL6707299A (es) * 1966-07-16 1968-01-17
GB1145544A (en) 1966-07-16 1969-03-19 Polichimica Sap S P A New tetrahydroindazoles
HUP0301301A2 (hu) 2000-06-23 2003-08-28 Takeda Chemical Industries Ltd. Benzoxazepinon-származékok és szkvalén szintáz inhibitorként való alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
US7112676B2 (en) 2002-11-04 2006-09-26 Hoffmann-La Roche Inc. Pyrimido compounds having antiproliferative activity
CN100448869C (zh) * 2002-11-27 2009-01-07 拜尔药品公司 用于治疗糖尿病的苯胺基吡唑衍生物
AR042067A1 (es) * 2002-11-27 2005-06-08 Bayer Pharmaceuticals Corp Derivados de anilinopirazol utiles en el tratamiento de la diabetes
EP1698335A4 (en) 2003-12-26 2007-08-01 Ono Pharmaceutical Co AGENT FOR PREVENTING AND / OR TREATING DISEASES INVOLVING A MITOCHONDRIAL BENZODIAZEPINE RECEPTOR
CA2628260A1 (en) 2005-11-09 2007-05-18 Abbott Laboratories 2-phenyl-2h-pyraz0le derivatives as p2x7 receptor antagonists and uses thereof
CA2631746A1 (en) 2005-12-01 2007-06-07 Bayer Healthcare Llc Urea compounds useful in the treatment of cancer

Also Published As

Publication number Publication date
CN102164900B (zh) 2014-04-16
IL211674A0 (en) 2011-06-30
EP2346834B1 (en) 2013-11-20
US20100076026A1 (en) 2010-03-25
MX2011002793A (es) 2011-04-05
EP2346834A1 (en) 2011-07-27
KR20110059890A (ko) 2011-06-07
ES2443947T3 (es) 2014-02-21
JP2012503618A (ja) 2012-02-09
US8153663B2 (en) 2012-04-10
CN102164900A (zh) 2011-08-24
AU2009295967A1 (en) 2010-04-01
CA2736434A1 (en) 2010-04-01
BRPI0919248A2 (pt) 2019-09-24
TW201020234A (en) 2010-06-01
WO2010034657A1 (en) 2010-04-01
JP5450632B2 (ja) 2014-03-26
KR101444988B1 (ko) 2014-09-26

Similar Documents

Publication Publication Date Title
AR073396A1 (es) Derivados de 3-amino-indazol o de 3-amino-4, 5, 6, 7-tetrahidro-indazol
AR073314A1 (es) Derivados de indazol o de 4,5,6,7-tetrahidro-indazol
CR10784A (es) Nuevos derivados de aminopirimidina como inhibidores de plki
PE20151781A1 (es) Piridonamidas como moduladores de canales de sodio
PE20161405A1 (es) Analogos de cortistatina y sintesis y usos de los mismos
AR085615A1 (es) Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen
AR060525A1 (es) Piridin [3,4-b] pirazinonas. composiciones farmaceuticas
PE20151951A1 (es) Heteroarildihidropirimidinas unidas por puentes en 6 para el tratamiento y la profilaxis de infeccion por el virus de la hepatitis b
AR054024A1 (es) Derivados de piridina -3- carboxamida como agonistas inversos de cb1
MA34644B1 (fr) Dérivés de pyrazole aminopyrimidine en tant que modulateurs du lrrk2
CL2020001919A1 (es) Inhibidores de endonucleasa cap-dependientes.
AR072962A1 (es) Derivados de pirimidin-4-ona sustituidos
PE20141682A1 (es) Derivados de (4-fenilimidazol-2-il) etilamina utiles como moduladores de canal de sodio
CR20110013A (es) Derivados de Heteroarilo como Inhibidores de DGAT1
MA35749B1 (fr) Dérivés nucléosidiques 4'-azido, 3'-fluoro substitués en tant qu'inhibiteurs de la réplication de l'arn du vhc
AR069480A1 (es) Derivados de 2-amino-pirimidina
EA201391209A1 (ru) Мостиковые производные пиперидина
PE20130155A1 (es) Derivados de ariletinilo
AR082886A1 (es) Compuestos y composiciones farmaceuticas que los contienen
ES2530943T3 (es) Derivados de la cromenona con actividad antitumoral
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
CU24039B1 (es) Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17
UY29393A1 (es) Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones.
AR083760A1 (es) Agentes antibacterianos y composiciones farmaceuticas
ES2567311T3 (es) 6-(3-Aza-biciclo[3.1.0]hex-3-il)-2-fenil-pirimidinas como antagonistas del receptor de ADP

Legal Events

Date Code Title Description
FB Suspension of granting procedure